PX 478

Drug Profile

PX 478

Alternative Names: PX-478

Latest Information Update: 21 Apr 2011

Price : $50

At a glance

  • Originator ProlX Pharmaceuticals
  • Developer Oncothyreon
  • Class Antineoplastics; Mustard compounds; Phenylpropionates; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Lymphoma; Solid tumours

Most Recent Events

  • 08 Jun 2010 Efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a Phase-I trial in Cancer presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010) ,
  • 14 May 2010 Oncothyreon completes a phase I trial in Solid tumours and lymphoma in USA
  • 16 Apr 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top